Phase II trial of S-1 monotherapy as adjuvant chemotherapy in triple negative breast cancer patients who did not achieve pathological complete response after neoadjuvant chemotherapy - Phase II trial of S-1 monotherapy as adjuvant chemotherapy in triple negative breast cancer patients who did not achieve pathological complete response after neoadjuvant chemotherapy(KBCSG01)

Kitasato University School of Medicine0 个研究点目标入组 30 人开始时间: 2010年10月6日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)patients receiving oral 5-FU based chemotherapy 2)with active double cancer 3)with severe complications (congested heart failure, coronary insufficiency, myocardial infarction, angina pectoris or abnormal cardiac rhythm which need to treat, history of cerebrovascular accident, hemorrhagic gastrointestinal ulceration, uncontrolled diabetes, renal failure, active hepatitis, liver cirrhosis) 4) pregnant or nursing women or women who like be pregnant and men with partner willing to get pregnant 5)with history of mental disorder or treating it at the moment 6)with history of severe allergy 7)with severe allergy to 5-FU based drug 8)patients receiving 5-FU based chemotherapy 9)patients receiving Flucytosine 10)Bilateral breast cancer, either simultaneous or metachronal 11)inflammatory breast cancer 12)Impossible to take oral drugs 13)doctor's decision not to be registered to this study

发起方

Kitasato University School of Medicine